Abstract
Pure red cell aplasia (PRCA) is a well-known although infrequent hematologic complication after allogeneic bone marrow transplantation. PRCA occurs in cases of major ABO-mismatch between donor and recipient and is believed to be due to inhibition of donor erythroid progenitors by residual host isohemagglutinins. We report a 10-year-old boy with post-hepatitis aplastic anemia (AA) who developed PRCA after HLA-matched familial peripheral blood stem cell transplantation (SCT) following conditioning with Cph 200 mg/kg + ATG 90 mg/kg. Granulocyte engraftment occurred on day +18, platelet engrafted on day +40, while reticulocytopenia at 0% persisted until day +118, and erythroid precursors were totally absent from bone marrow. After a single dose of rituximab 200 mg/m2administered on day +118 PRCA resolved and on day +132 the reticulocytes rose to 5.7%. On day +139 the Hb reached 137 g/l and the erythroid lineage in BM increased to 21%. We conclude that due to the rapid recovery from PRCA and lack of side effects, rituximab should be tried as first-line treatment of PRCA after allo-SCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lee JH, Lee KH, Kim S et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation Bone Marrow Transplant 2000 25: 179 184
Yang MH, Hsu HC . Pure red cell aplasia after ABO-incompatible allogeneic stem cell transplantation in severe aplastic anemia with response to steroids: a case report and literature review Ann Hematol 2001 80: 299 301
Bolan CD, Leitman SF, Griffith LM et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation Blood 2001 98: 1687 1694
Veelken H, Wasch R, Behringer D et al. Pure red cell aplasia after allogeneic stem cell transplantation with reduced conditioning Bone Marrow Transplant 2000 26: 911 915
Ustun C, Celebi H, Arat M et al. Treatment of aregeneratoric anemia following an ABO-incompatible allogeneic peripheral blood stem cell transplantation: a case report Ther Apher 1999 3: 275 277
Ohta S, Yokoyama H, Ise T et al. Apheresis therapy for prolonged red cell aplasia after major ABO-mismatched bone marrow transplantation Intern Med 1997 36: 487 491
Martelli M, Ponchio L, Beguin Y et al. Pure red cell aplasia following peripheral stem cell transplantation: complete response to a short course of high-dose recombinant human erythropoietin Haematologica 1994 79: 456 459
Ohashi K, Akiyama H, Takamoto S et al. Treatment of pure red cell aplasia after major ABO-incompatible bone marrow transplantation resistant to erythropoietin. Bone Marrow Transplantation Team Bone Marrow Transplant 1994 13: 335 336
Bavaro P, Di Girolamo G, Olioso P et al. Donor lymphocyte infusion as therapy for pure red cell aplasia following bone marrow transplantation Br J Haematol 1999 104: 930 931
Selleri C, Raiola A, De Rosa G et al. CD34+-enriched donor lymphocyte infusions in a case of pure red cell aplasia and late graft failure after major ABO-incompatible bone marrow transplantation Bone Marrow Transplant 1998 22: 605 607
Roychowdhury DF, Linker CA . Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin Bone Marrow Transplant 1995 16: 471 472
Labar B, Bogdanic V, Nemet D et al. Antilymphocyte globulin for treatment of pure red cell aplasia after major ABO incompatible marrow transplant Bone Marrow Transplant 1992 10: 471 472
Zecca M, De Stefano P, Nobili B, Locatelli F . Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia Blood 2001 97: 3995 3997
Stasi R, Pagano A, Stipa E, Amadori S . Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura Blood 2001 98: 952 957
Acknowledgements
The authors wish to thank Kathy Turner for reading and correcting the manuscript and the Advisory Board Foundation for their continuing support of treatment of children with aplastic anemia in Russia.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maschan, A., Skorobogatova, E., Balashov, D. et al. Successful treatment of pure red cell aplasia with a single dose of rituximab in a child after major ABO incompatible peripheral blood allogeneic stem cell transplantation for acquired aplastic anemia. Bone Marrow Transplant 30, 405–407 (2002). https://doi.org/10.1038/sj.bmt.1703668
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703668
Keywords
This article is cited by
-
Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question
Bone Marrow Transplantation (2021)
-
Oral High Dose Dexamethasone for Pure Red Cell Aplasia Following ABO-Mismatched Allogeneic Peripheral Blood Stem Cell Transplantation: A Case Report
Indian Journal of Hematology and Blood Transfusion (2015)
-
Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation
Bone Marrow Transplantation (2011)
-
Impact of ABO incompatibility on engraftment and transfusion requirement after unrelated cord blood transplantation: a single institute experience in Japan
Bone Marrow Transplantation (2007)
-
Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies
Annals of Hematology (2007)